PL378214A1 - Pochodne karbostyrylu i inhibitory wychwytu zwrotnego serotoniny do leczenia zaburzeń nastroju - Google Patents
Pochodne karbostyrylu i inhibitory wychwytu zwrotnego serotoniny do leczenia zaburzeń nastrojuInfo
- Publication number
- PL378214A1 PL378214A1 PL378214A PL37821403A PL378214A1 PL 378214 A1 PL378214 A1 PL 378214A1 PL 378214 A PL378214 A PL 378214A PL 37821403 A PL37821403 A PL 37821403A PL 378214 A1 PL378214 A1 PL 378214A1
- Authority
- PL
- Poland
- Prior art keywords
- serotonin reuptake
- mood disorders
- treatment
- reuptake inhibitors
- carbostyril derivatives
- Prior art date
Links
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 title abstract 3
- 208000019022 Mood disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 abstract 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 abstract 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 abstract 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004372 aripiprazole Drugs 0.000 abstract 1
- 229960001653 citalopram Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229960002866 duloxetine Drugs 0.000 abstract 1
- 229960004341 escitalopram Drugs 0.000 abstract 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 abstract 1
- 229960002464 fluoxetine Drugs 0.000 abstract 1
- 229960004038 fluvoxamine Drugs 0.000 abstract 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 229960000600 milnacipran Drugs 0.000 abstract 1
- 229960002296 paroxetine Drugs 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229960002073 sertraline Drugs 0.000 abstract 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004688 venlafaxine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002379003 | 2002-12-27 | ||
| US47048103P | 2003-05-14 | 2003-05-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL378214A1 true PL378214A1 (pl) | 2006-03-20 |
| PL211975B1 PL211975B1 (pl) | 2012-07-31 |
Family
ID=32716306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378214A PL211975B1 (pl) | 2002-12-27 | 2003-12-25 | Kompozycja farmaceutyczna zawierająca pochodną karbostyrylu i inhibitor wychwytu zwrotnego serotoniny oraz jej zastosowanie do leczenia zaburzeń nastroju |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US9387182B2 (pl) |
| EP (2) | EP1723957A3 (pl) |
| JP (1) | JP4284524B2 (pl) |
| KR (2) | KR100842694B1 (pl) |
| CN (2) | CN1726039B (pl) |
| AT (1) | ATE376419T1 (pl) |
| AU (1) | AU2003295235B2 (pl) |
| BR (1) | BR0317771A (pl) |
| CA (1) | CA2511619C (pl) |
| CY (1) | CY1108060T1 (pl) |
| DE (1) | DE60317098T2 (pl) |
| DK (1) | DK1575590T3 (pl) |
| EC (1) | ECSP055885A (pl) |
| ES (1) | ES2295677T3 (pl) |
| HK (3) | HK1082411A1 (pl) |
| IL (1) | IL169358A (pl) |
| MX (1) | MXPA05006857A (pl) |
| MY (1) | MY152919A (pl) |
| NO (1) | NO333291B1 (pl) |
| NZ (2) | NZ540054A (pl) |
| PE (1) | PE20040923A1 (pl) |
| PL (1) | PL211975B1 (pl) |
| PT (1) | PT1575590E (pl) |
| RU (2) | RU2356554C2 (pl) |
| SI (1) | SI1575590T1 (pl) |
| WO (1) | WO2004060374A1 (pl) |
| ZA (1) | ZA200503873B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004243096B2 (en) * | 2003-05-23 | 2008-12-18 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| EP1797039A1 (en) * | 2004-09-13 | 2007-06-20 | Matrix Laboratories Ltd | Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts |
| AU2005302589B2 (en) * | 2004-10-28 | 2010-09-16 | Sk Biopharmaceuticals Co., Ltd. | Adjunctive therapy for depression |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
| JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US20150174247A1 (en) | 2012-06-29 | 2015-06-25 | Maruishi Pharmaceutical Co., Ltd. | Oral pharmaceutical preparation of aripiprazole |
| GB2542155B (en) | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
| CN108642129A (zh) * | 2018-05-03 | 2018-10-12 | 杭州端丽生物技术有限公司 | 冲动控制紊乱生物检测标记物和Impulsins的医药用途 |
| JP7211136B2 (ja) * | 2019-02-14 | 2023-01-24 | ニプロ株式会社 | 錠剤、および、その製造方法 |
| CN114340607A (zh) | 2019-05-13 | 2022-04-12 | 瓦西特拉有限公司 | 利用自噬激活预防或治疗退行性脑部疾病的药物组合物 |
| EP3970711A4 (en) | 2019-05-15 | 2023-07-05 | VASTHERA Co. Ltd. | COMPOSITION FOR PREVENTING OR TREATING CARDIO-CEREBRO-VASCULAR DISEASES COMPRISING AS ACTIVE PRINCIPLE AN AUTOPHAGY ACTIVATOR |
| US11080484B1 (en) * | 2020-10-08 | 2021-08-03 | Omniscient Neurotechnology Pty Limited | Natural language processing of electronic records |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310524A (en) | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP2608788B2 (ja) | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5591884A (en) | 1989-05-31 | 1997-01-07 | Abbott Laboratories | Dopamine agonists |
| US5500343A (en) | 1990-02-07 | 1996-03-19 | Board Of Regents, The University Of Texas System | Allelic association of the human dopamine(D2) receptor gene in compulsive disorders |
| US5780051A (en) | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
| US5663167A (en) | 1992-12-09 | 1997-09-02 | The United States Of America As Represented By The Department Of Health And Human Services | Antipsychotic composition and method of treatment |
| IE930485A1 (en) | 1993-06-28 | 1994-12-28 | Hemisphere Ltd | Antidepressant agents with a rapid onset of action |
| ZA948357B (en) | 1994-06-16 | 1996-04-24 | Lilly Co Eli | Potentiation of drug response |
| WO1997023220A1 (en) | 1995-12-22 | 1997-07-03 | Eli Lilly And Company | Method for treating depression |
| JP2000507544A (ja) | 1996-03-25 | 2000-06-20 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
| IL126203A (en) | 1996-03-25 | 2002-12-01 | Lilly Co Eli | A synergistic painkiller that contains olenzapine and another painkiller |
| US6159963A (en) | 1996-03-29 | 2000-12-12 | Eli Lilly And Company | Method for treating substance abuse |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| ZA982368B (en) | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
| WO1999020279A1 (en) | 1997-10-17 | 1999-04-29 | Eli Lilly And Company | Potentiation of pharmaceuticals |
| GB9801538D0 (en) | 1998-01-23 | 1998-03-25 | Merck Sharp & Dohme | Pharmaceutical product |
| AU765603C (en) | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
| GB2336534A (en) | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
| ATE283694T1 (de) | 1998-05-08 | 2004-12-15 | Upjohn Co | Neue arzneimittelkombinationen aus reboxetin und pindolol |
| US6500827B2 (en) | 1998-05-08 | 2002-12-31 | Pharmacia & Upjohn Company | Drug combinations |
| CA2332253A1 (en) | 1998-05-21 | 1999-11-25 | Eli Lilly And Company | Combination therapy for treatment of depression |
| US6960577B2 (en) | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| JP2002516282A (ja) | 1998-05-22 | 2002-06-04 | イーライ・リリー・アンド・カンパニー | 難治性鬱病の処置のための組合せ治療 |
| US20030027817A1 (en) | 1998-05-29 | 2003-02-06 | Tollefson Gary Dennis | Combination therapy for treatment of bipolar disorders |
| EA003611B1 (ru) | 1998-05-29 | 2003-06-26 | Эли Лилли Энд Компани | Комбинационная терапия для лечения биполярных расстройств |
| US6420349B1 (en) | 1998-08-24 | 2002-07-16 | Bristol-Myers Squibb Company | Isoxazolinone antibacterial agents |
| AU757874B2 (en) | 1998-11-23 | 2003-03-06 | Sepracor, Inc. | 2-hydroxymethylolanzapine compositions and methods |
| AU757870B2 (en) | 1998-11-23 | 2003-03-06 | Sepracor, Inc. | Pharmaceutical compositions containing olanzapine-N-oxide |
| PT1133300E (pt) | 1998-11-23 | 2005-04-29 | Sepracor Inc | Composicoes de desmetilolanzapina e metodos |
| EP1165090A2 (en) | 1999-03-18 | 2002-01-02 | Children's Hospital Research Foundation | A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| AU4062900A (en) | 1999-04-06 | 2000-10-23 | Sepracor, Inc. | Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites |
| US6281207B1 (en) | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
| US6599532B2 (en) | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
| US6572890B2 (en) | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| US6322503B1 (en) | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
| DE10018834A1 (de) | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| CA2431041A1 (en) | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| US20020123490A1 (en) | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| WO2002072145A1 (fr) | 2001-03-14 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif |
| SK12822003A3 (sk) | 2001-04-19 | 2004-04-06 | Warner - Lambert Company Llc | Fúzne bicyklické alebo tricyklické aminokyseliny |
| US20030109546A1 (en) | 2001-04-26 | 2003-06-12 | Fenton Wayne S. | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
| DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US6582737B2 (en) | 2001-09-25 | 2003-06-24 | Peirce Management, Llc | Pharmaceutical composition containing two active ingredients for smoking cessation |
| MXPA04007752A (es) | 2002-02-08 | 2005-06-17 | Abbott Lab | Terapia de combinacion para tratamiento de esquizofrenia. |
| EP1336406A1 (en) | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
| AU2003227521A1 (en) | 2002-05-30 | 2003-12-19 | Neurosearch A/S | Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain |
| US20040127489A1 (en) | 2002-07-29 | 2004-07-01 | David Pickar | Novel antipsychotic combination therapies and compositions useful therein |
| EP1551393A4 (en) | 2002-07-30 | 2010-06-16 | Peter Migaly | COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS |
| WO2004039361A1 (en) | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| AU2004243096B2 (en) | 2003-05-23 | 2008-12-18 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| MXPA06002778A (es) | 2003-09-09 | 2006-06-14 | Pfizer Prod Inc | Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina. |
| WO2005051488A1 (en) | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Combination of dopamine agonists and monoamine reuptake inhibitors |
| WO2005053703A1 (en) | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
-
2003
- 2003-12-25 BR BR0317771-8A patent/BR0317771A/pt active Search and Examination
- 2003-12-25 AU AU2003295235A patent/AU2003295235B2/en not_active Ceased
- 2003-12-25 NZ NZ540054A patent/NZ540054A/en not_active IP Right Cessation
- 2003-12-25 KR KR1020057012073A patent/KR100842694B1/ko active IP Right Grant
- 2003-12-25 DK DK03786308T patent/DK1575590T3/da active
- 2003-12-25 CN CN2003801061036A patent/CN1726039B/zh not_active Expired - Fee Related
- 2003-12-25 AT AT03786308T patent/ATE376419T1/de active
- 2003-12-25 PT PT03786308T patent/PT1575590E/pt unknown
- 2003-12-25 MX MXPA05006857A patent/MXPA05006857A/es active IP Right Grant
- 2003-12-25 SI SI200331078T patent/SI1575590T1/sl unknown
- 2003-12-25 EP EP06017539A patent/EP1723957A3/en not_active Withdrawn
- 2003-12-25 RU RU2005123808/15A patent/RU2356554C2/ru not_active IP Right Cessation
- 2003-12-25 CA CA2511619A patent/CA2511619C/en not_active Expired - Lifetime
- 2003-12-25 CN CN2007100016207A patent/CN1989968B/zh not_active Expired - Fee Related
- 2003-12-25 NZ NZ556779A patent/NZ556779A/en not_active IP Right Cessation
- 2003-12-25 KR KR1020077017722A patent/KR100858852B1/ko not_active IP Right Cessation
- 2003-12-25 ES ES03786308T patent/ES2295677T3/es not_active Expired - Lifetime
- 2003-12-25 EP EP03786308A patent/EP1575590B1/en not_active Expired - Lifetime
- 2003-12-25 DE DE60317098T patent/DE60317098T2/de not_active Expired - Lifetime
- 2003-12-25 WO PCT/JP2003/016724 patent/WO2004060374A1/en active Application Filing
- 2003-12-25 PL PL378214A patent/PL211975B1/pl unknown
- 2003-12-26 JP JP2003433429A patent/JP4284524B2/ja not_active Expired - Lifetime
-
2004
- 2004-01-05 PE PE2004000001A patent/PE20040923A1/es not_active Application Discontinuation
-
2005
- 2005-05-12 NO NO20052359A patent/NO333291B1/no not_active IP Right Cessation
- 2005-05-13 ZA ZA200503873A patent/ZA200503873B/en unknown
- 2005-06-21 EC EC2005005885A patent/ECSP055885A/es unknown
- 2005-06-23 IL IL169358A patent/IL169358A/en not_active IP Right Cessation
-
2006
- 2006-03-03 HK HK06102790.2A patent/HK1082411A1/xx not_active IP Right Cessation
-
2007
- 2007-08-30 HK HK07109436.6A patent/HK1101550A1/xx not_active IP Right Cessation
- 2007-11-08 CY CY20071101436T patent/CY1108060T1/el unknown
-
2008
- 2008-07-29 RU RU2008131331/15A patent/RU2389490C2/ru not_active IP Right Cessation
- 2008-12-19 MY MYPI20085175 patent/MY152919A/en unknown
-
2010
- 2010-12-16 HK HK10111807.8A patent/HK1145291A1/xx not_active IP Right Cessation
-
2014
- 2014-04-15 US US14/252,907 patent/US9387182B2/en not_active Expired - Lifetime
-
2016
- 2016-06-08 US US15/176,464 patent/US9694009B2/en not_active Expired - Lifetime
-
2017
- 2017-05-25 US US15/604,720 patent/US20170258788A1/en not_active Abandoned
-
2019
- 2019-01-08 US US16/242,315 patent/US20190151308A1/en not_active Abandoned
- 2019-10-28 US US16/664,984 patent/US20200289501A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY152919A (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| RS20050392A (en) | Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor | |
| MY134110A (en) | Combinations of reboxetine and neuroleptic agents | |
| MY133238A (en) | Monoamine reuptake inhibitors for treatment for cns disorders | |
| CY1112932T1 (el) | Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς | |
| WO2004010932A3 (en) | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions | |
| BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
| AR098599A2 (es) | Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo | |
| BR0306147A (pt) | Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição | |
| EP1254668A3 (en) | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression | |
| CA2525524A1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| IL172134A0 (en) | Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders | |
| BRPI0413750A (pt) | uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit | |
| RS51669B (en) | NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE | |
| Salzman et al. | Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study. | |
| MXPA06002778A (es) | Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina. | |
| EP1260221A3 (en) | Combination treatment for depression and anxiety | |
| SE9803155D0 (sv) | A new composition | |
| Koran | Sertraline reduced patient dropout rates and acute exacerbation of symptoms in obsessive compulsive disorder | |
| new SSRI–escitalopram | Escitalopram: refining a commonly prescribed SSRI | |
| BRPI0415280A (pt) | métodos para o tratamento de sintomas vasomotores |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification |